132 related articles for article (PubMed ID: 38388178)
1. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion.
Jamieson A; Grube M; Leung S; Chiu D; Lum A; Kwon JS; Talhouk A; Gilks B; Kommoss S; McAlpine JN
Int J Gynecol Cancer; 2024 Apr; 34(4):544-549. PubMed ID: 38388178
[TBL] [Abstract][Full Text] [Related]
2. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
3. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.
Kang EY; Wiebe NJ; Aubrey C; Lee CH; Anglesio MS; Tilley D; Ghatage P; Nelson GS; Lee S; Köbel M
J Pathol Clin Res; 2022 Jan; 8(1):19-32. PubMed ID: 34596362
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging.
Gultekin M; Guler OC; Yuce Sari S; Akkus Yildirim B; Onal C; Celik H; Yuce K; Ayhan A; Arik Z; Kose F; Altundag O; Zoto Mustafayev T; Atalar B; Bolukbasi Y; Yildiz F
J Obstet Gynaecol; 2021 Apr; 41(3):414-420. PubMed ID: 32347768
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
7. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy.
Chang-Halpenny CN; Natarajan S; Hwang-Graziano J
Gynecol Oncol; 2013 Dec; 131(3):598-603. PubMed ID: 24135679
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy.
Diavolitsis V; Rademaker A; Lurain J; Hoekstra A; Strauss J; Small W
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):415-9. PubMed ID: 22365625
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of recurrence in early-stage endometrial carcinoma after delays in adjuvant radiation treatment.
Zhu S; Khalil R; Altairy O; Burmeister C; Dimitrova I; Elshaikh M
Int J Gynecol Cancer; 2021 Jan; 31(1):73-77. PubMed ID: 33087415
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
11. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
12. Vaginal brachytherapy management of stage I and II endometrial cancer.
van den Heerik ASVM; Horeweg N; Creutzberg CL; Nout RA
Int J Gynecol Cancer; 2022 Mar; 32(3):304-310. PubMed ID: 35256416
[TBL] [Abstract][Full Text] [Related]
13. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage Ib-II endometrial cancer: an Italian multicenter retrospective study (CTF study).
Gadducci A; Cosio S; Landoni F; Maggino T; Zola P; Sostegni B; Bellicini A; Fuso L; Cristofani R; Sartori E
Gynecol Oncol; 2014 Jul; 134(1):29-35. PubMed ID: 24769176
[TBL] [Abstract][Full Text] [Related]
15. Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study.
Ørtoft G; Høgdall C; Hansen ES; Dueholm M
J Gynecol Oncol; 2020 Mar; 31(2):e22. PubMed ID: 31912677
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
17. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.
Morrow CP; Bundy BN; Kurman RJ; Creasman WT; Heller P; Homesley HD; Graham JE
Gynecol Oncol; 1991 Jan; 40(1):55-65. PubMed ID: 1989916
[TBL] [Abstract][Full Text] [Related]
18. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
19. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer.
Yerramilli D; Chen YH; Venkatachalam V; Alban GM; Buscariollo DL; Cheng T; King MT; Pretz JL; Russo AL; Lee LJ
Pract Radiat Oncol; 2021; 11(5):394-403. PubMed ID: 34015544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
